Itamar Medical is a medical technology company developing products based on its proprietary PAT signal, which provides a noninvasive view into the cardiovascular system and the autonomic nervous system. The company's EndoPAT is an FDA-cleared device for assessing arterial (endothelial) function. It has been established in numerous peer-reviewed studies as the "sum of all risk factors" and an independent predictor of heart disease prognosis. Itamar Medical's WatchPAT device is an FDA-cleared portable diagnostic device that provides accurate screening, detection, and follow-up in the treatment of sleep apnea. The WatchPAT test can be performed in the comfort of the patient's home and generates accurate clinical data validated against PSG. The device has been used by more than 800,000 patients worldwide. In June 2019, the company received FDA approval for its WatchPAT One, a single-use version of its existing product, WatchPAT 300. While the previous product's data could only be extracted in a lab, the new product synchronizes the data in real time with the user's phone via an app.